Comparative analysis of antibody responses to SARS-CoV-2 in various populations
Received:January 20, 2021  Revised:April 20, 2021
View Full Text  View/Add Comment  Download reader
DOI:10.46701/BG.2021012021102
KeyWord:SARS-CoV-2  serological assay  nucleocapsid protein  receptor-binding domain  spike protein  neutralizing antibody
                       
AuthorInstitution
Lei Liu Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China;Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China
Wanbing Liu Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China
Yan Liu Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China;Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China
Guomei Kou Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China
Yaqiong Zheng Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China
Liping Cai Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China
Shengdian Wang CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
Shangen Zheng Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China;Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China
Hits: 1474
Download times: 2900
Abstract:
      This paper aimed to analyze antibody responses to SARS-CoV-2 in various populations. Two hundred and six COVID-19 patients, 46 convalescent patients, and 270 healthy population were enrolled. Antibodies against nucleocapsid protein (N) and spike protein's receptor-binding domain (RBD), and neutralizing antibody were detected. The results demonstrated both anti-N and anti-RBD antibodies could be detected in about 80% of COVID-19 patients and 90% of convalescent patients, while no antibodies could be detected in some convalescents and patients even after 14 days post-onset of symptoms. The level of anti-RBD antibody strongly correlated with the neutralizing activity of sera from these two cohorts. The titer of neutralizing antibody was lower in convalescents than that in active COVID-19 patients. In addition, the titer of neutralizing antibody was less than 1:80 in none of the severe COVID-19 patients, 18.8% in non-severe COVID-19 patients, and 32.6% in convalescents. The study suggests that the level of anti-RBD antibody is closely related to neutralization activity in COVID-19 patients and convalescents. Some SARS-CoV-2-infected cases trigger a weak antiviral immune response, and the level of neutralizing antibody may have a faster decay rate.
Close